Vertical: CNMBase Year: 2025
Market Size (2025)
$215.47M
Projected (2032)
$306.19M
CAGR (2022–2032)
5.2%
Key Players
12+
Market Overview
The global eubiotics market was valued at USD 215.47 million in 2025 and is projected to reach USD 306.19 million by 2032, registering a CAGR of 5.15% over 2026–2032. Between 2025 and 2032 the market is expected to add USD 90.72 million in absolute value. The market has expanded steadily from USD 185.29 million in 2022, supported by the progressive withdrawal of antibiotic growth promoters from livestock production, the growing commercial focus on gut health as a driver of feed efficiency, and continued growth in global poultry and pork output.
Eubiotics are feed additives that help establish and maintain a favourable balance of the gastrointestinal microbiota in livestock. The category spans organic acids, probiotics (direct-fed microbials), prebiotics, and essential oils and other phytogenic compounds. Producers use these additives to support nutrient digestibility, intestinal integrity and resilience to enteric challenges, particularly in production systems that have reduced or eliminated the routine use of in-feed antibiotics.
Key Findings
Product type: Organic Acids is the largest product type, valued at USD 75.41 million in 2025 (35.0% share). Probiotics is the fastest-growing product type, with a CAGR of 6.93% over 2026–2032, rising from USD 53.87 million in 2025 to USD 86.19 million in 2032.
Livestock: Poultry is the largest livestock category, valued at USD 107.73 million in 2025 (50.0% share), and it is also the fastest-growing category with a CAGR of 5.66%.
Region: Asia Pacific is both the leading and the fastest-growing region, accounting for USD 68.95 million (32.0%) of global revenue in 2025 and expanding at a CAGR of 6.16% to reach USD 104.84 million by 2032.
Country: The U.S. is the leading country market, valued at USD 36.03 million in 2025, while India is the fastest-growing country market with a CAGR of 8.28% over 2026–2032.
Segmentation Summary
By product type, the market is segmented into Organic Acids, Probiotics, Prebiotics, and Essential Oils & Others. Organic Acids holds the largest position at USD 75.41 million in 2025, reflecting its long history of use as acidifiers and feed preservatives in swine and poultry diets. Probiotics (USD 53.87 million, 25.0%) is the second-largest product type and the fastest growing at 6.93%, followed by Prebiotics at 5.92%. Prebiotics and Essential Oils & Others each account for USD 43.09 million (20.0%) in 2025; Prebiotics is forecast to reach USD 64.45 million and Essential Oils & Others USD 58.02 million by 2032.
By livestock, the market is segmented into Poultry, Swine and Others. Poultry accounts for 50.0% of 2025 revenue (USD 107.73 million), owing to the scale of broiler and layer production and the sensitivity of short-cycle birds to enteric disease. Swine follows with USD 64.64 million (30.0%), growing at 4.06%, while the Others category, which includes ruminants, aquaculture and other species, is valued at USD 43.09 million and grows at 5.41%.
By region, Asia Pacific (USD 68.95 million) is followed by Europe (USD 60.33 million, 28.0%), North America (USD 47.40 million, 22.0%), Latin America (USD 28.01 million, 13.0%) and Middle East & Africa (USD 10.77 million, 5.0%). Latin America (5.62%) and Middle East & Africa (5.56%) are forecast to grow faster than the global average, while Europe (4.18%) and North America (4.41%) are more mature markets with moderate growth.
Competitive Landscape Summary
The global eubiotics market is moderately fragmented. A group of large animal nutrition and biosolutions companies, including dsm-firmenich (Animal Nutrition & Health), Novonesis, Cargill, ADM, Kemin Industries and Adisseo, compete alongside specialist suppliers such as Lallemand Animal Nutrition, Anpario and the eubiotics businesses of Evonik, Alltech, Novus International and Nutreco (Trouw Nutrition/Selko). Competition is based on strain and formulation intellectual property, documented efficacy, regulatory authorisations, technical service and access to premix and feed mill channels. Since 2022 the industry has seen significant portfolio restructuring, including the completion of the Novozymes–Chr. Hansen merger that formed Novonesis in January 2024, dsm-firmenich's agreement in February 2026 to divest its Animal Nutrition & Health business to CVC Capital Partners, and bolt-on acquisitions of phytogenic and probiotic specialists by Cargill, Adisseo, Anpario and Lallemand.
Challenges and Opportunities
The principal challenges facing the market are variability in field performance compared with the antibiotics that eubiotics are replacing, the cost and duration of regulatory approval for new strains and actives, and volatility in livestock producer margins, which constrains spending on feed additives during downturns. Disease shocks, such as African swine fever and highly pathogenic avian influenza, can also reduce animal numbers in affected markets.
Opportunities are concentrated in three areas: the continued phase-out of antimicrobial growth promoters in emerging livestock economies, where poultry production is expanding fastest; the development of combination and precision products that pair probiotics, prebiotics, organic acids and phytogenics with microbiome analytics; and new application areas, including aquaculture, ruminants and companion animals, which are captured within the Others livestock category.
Future Outlook
The market is forecast to grow from USD 226.57 million in 2026 to USD 306.19 million in 2032. Growth will be led by Probiotics and Prebiotics on the product side, by Poultry on the livestock side, and by Asia Pacific geographically, where the market is expected to add USD 35.89 million between 2025 and 2032. Over the forecast period, Organic Acids is expected to remain the largest product type, although its share is projected to decline from 35.0% in 2025 to 31.9% in 2032 as biological products gain share. Suppliers able to demonstrate consistent, measurable returns on feed efficiency and animal health, supported by local technical service, are expected to be best placed to capture this growth.
The Eubiotics Market market is projected to grow at a CAGR of 5.2% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Eubiotics are non-antibiotic feed additives that promote a healthy balance of the gastrointestinal microflora in production animals and thereby support digestion, nutrient absorption, gut barrier function and overall performance. The term derives from the Greek "eu" (good) and "bios" (life). Eubiotics act through several mechanisms: lowering gut and feed pH, inhibiting pathogenic bacteria, competitively excluding pathogens, supplying substrates for beneficial bacteria, and modulating immune and inflammatory responses in the intestine.
For the purpose of this study, the eubiotics market includes the following product categories:
Organic Acids: short- and medium-chain organic acids and their salts used as acidifiers in feed and drinking water, including formic, propionic, lactic, citric, fumaric, benzoic and butyric acid and their blends, as well as protected or coated forms.
Probiotics: live microbial feed additives (direct-fed microbials), including Bacillus spore-formers, lactic acid bacteria and live yeasts.
Prebiotics: non-digestible feed ingredients that selectively stimulate beneficial gut bacteria, such as mannan-oligosaccharides, fructo-oligosaccharides, inulin, beta-glucans and yeast cell wall fractions.
Essential Oils & Others: essential oils and phytogenic (plant-derived) additives such as thymol, carvacrol, cinnamaldehyde and plant extracts, together with other eubiotic products not classified elsewhere.
The market value represents revenue from the sale of these additives for use in livestock feed and water, measured at the manufacturer level. Excluded from the scope are antibiotics and other veterinary medicinal products, feed enzymes sold as stand-alone products, mycotoxin binders, vitamins, amino acids and trace minerals, and probiotic or prebiotic products intended for human consumption.
Scope of the Study
This report covers the global eubiotics market and its segmentation as follows:
By Product Type: Organic Acids, Probiotics, Prebiotics, Essential Oils & Others
By Livestock: Poultry, Swine, Others
By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, with country-level analysis for 20 countries and sub-regions
Timeline: historic years 2022–2024, base year 2025, forecast period 2026–2032
Currency and unit: USD Million
Research Objectives
To estimate the size of the global eubiotics market in value terms for the historic period 2022–2024 and the base year 2025, and to forecast it for 2026–2032.
To analyse the market by product type (Organic Acids, Probiotics, Prebiotics, Essential Oils & Others) and by livestock (Poultry, Swine, Others).
To assess market size and growth across five regions and their constituent countries and sub-regions.
To identify the drivers, restraints, opportunities and challenges shaping demand for eubiotics, with particular reference to antibiotic growth promoter restrictions and livestock production trends.
To evaluate the regulatory frameworks that govern the authorisation and use of eubiotic feed additives in major regions.
To analyse the value chain and the competitive forces operating in the market.
To profile the competitive landscape, including the positioning of leading suppliers and key developments since 2022.
To identify high-growth segments and geographies for suppliers, investors and feed industry stakeholders.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage research process combining secondary research, primary research and analytical modelling. The process began with defining the market scope and segmentation, followed by extensive desk research to build an initial understanding of the market, its participants and its regulatory environment. Primary interviews with industry participants were then used to validate assumptions, fill data gaps and refine estimates. Market size was estimated using both top-down and bottom-up approaches, and the results were triangulated to arrive at final figures. Forecasts were developed by modelling the effect of identified growth factors on each segment and region.
Stage 1 – Scoping: definition of the market, product categories, livestock categories and geographies.
Stage 2 – Secondary research: collection of data on livestock populations, feed production, additive usage, prices, regulations and company activity.
Stage 3 – Primary research: interviews with supply-side and demand-side participants to validate findings.
Stage 4 – Market estimation: construction of top-down and bottom-up models and data triangulation.
Stage 5 – Forecasting and validation: projection of market values to 2032 and final review of results for consistency.
Secondary Research
Secondary research provided the foundation for market definition, the identification of market participants and the collection of historical data. Sources relevant to the animal feed additives industry included:
Industry associations: International Feed Industry Federation (IFIF), FEFANA (EU Association of Specialty Feed Ingredients and their Mixtures), FEFAC (European Feed Manufacturers' Federation), American Feed Industry Association (AFIA), Association of American Feed Control Officials (AAFCO), China Feed Industry Association and the Compound Livestock Feed Manufacturers Association (CLFMA) of India.
Government and regulatory bodies: U.S. Food and Drug Administration (Center for Veterinary Medicine), U.S. Department of Agriculture, European Food Safety Authority (FEEDAP Panel), the European Commission's European Union Register of Feed Additives, China's Ministry of Agriculture and Rural Affairs, India's Department of Animal Husbandry and Dairying, Brazil's Ministry of Agriculture and Livestock, and the Food and Agriculture Organization of the United Nations.
Company sources: annual reports, financial statements, investor presentations, product literature and press releases of feed additive manufacturers and distributors.
Trade journals and publications: specialised animal nutrition and feed industry publications, along with peer-reviewed journals in animal science, veterinary microbiology and poultry science.
Paid databases: trade statistics, company information and industry databases used to validate production, trade and pricing information.
Primary Research
Primary research was conducted through in-depth telephone and online interviews with participants across the eubiotics value chain. The objectives were to validate the market definition and segmentation, verify secondary data, gather insight into pricing, adoption rates and purchasing behaviour, and obtain qualitative views on market drivers, restraints and future outlook.
Supply-side respondents included product managers, technical directors, regional sales heads and business development executives at eubiotic manufacturers, raw material suppliers and premix producers. Demand-side respondents included nutritionists and procurement managers at integrated poultry and swine producers, compound feed manufacturers, livestock veterinarians and distributors of feed additives. Interview findings were used to adjust assumptions on usage rates, inclusion levels, price points and regional adoption.
Market Size Estimation
Top-down approach: The overall animal feed additives market was used as the starting point, and the share attributable to eubiotics was estimated using industry data and expert input. This value was then allocated across product types, livestock categories and regions based on usage patterns, regulatory conditions and livestock production.
Bottom-up approach: Livestock populations and compound feed production volumes by species and country were combined with estimated eubiotic inclusion rates and penetration levels to derive consumption volumes. Volumes were multiplied by average selling prices for each product type to arrive at country-level values, which were aggregated to regional and global totals. Revenues of key market participants were also mapped to validate the overall market size.
Data triangulation: The results of the top-down and bottom-up approaches were compared, and differences were reconciled through further secondary research and primary interviews. The final estimates reflect the convergence of these methods and ensure consistency between segment, regional and global values.
Forecasting Methodology
The forecast was developed by projecting the base-year (2025) market values for each segment and country through 2032. The factors considered included:
Growth in poultry, swine and other livestock production and compound feed output by country.
The pace and scope of regulatory restrictions on antibiotic growth promoters and therapeutic zinc oxide.
Trends in eubiotic penetration and inclusion rates across species and production systems.
Average selling price trends by product type, including the effect of raw material costs.
New product launches, regulatory approvals and technology developments.
Macroeconomic indicators, including GDP growth, population, income levels and protein consumption.
Each factor was assessed for its expected impact over the short, medium and long term, and the resulting growth rates were applied by segment and region. The forecasts were reviewed with industry participants for reasonableness.
Assumptions and Limitations
All values are expressed in nominal USD Million; the effect of currency fluctuations has been accounted for using average annual exchange rates for the historic years and constant rates for the forecast period.
The regulatory environment is assumed to continue its present direction, with no reversal of existing restrictions on antibiotic growth promoters in major markets.
Livestock production is assumed to follow its long-term trend, without a prolonged global disruption on the scale of a pandemic.
Market values are calculated at the manufacturer level and exclude distributor and retail margins.
Data availability is more limited for some emerging markets, particularly in the Rest of Middle East & Africa and Rest of Latin America groupings, where estimates rely more heavily on primary research and proxy indicators.
Private companies do not disclose segment revenues; their positions are therefore assessed qualitatively.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global eubiotics market is moderately fragmented. A small number of large animal nutrition, ingredients and biosolutions companies offer broad portfolios across several eubiotic classes, supported by global manufacturing, regulatory and technical service capabilities. Alongside them, a larger number of specialists focus on particular product classes, such as probiotics, yeast derivatives, phytogenics or organic acid blends, and many regional formulators compete in organic acids and phytogenic blends, particularly in Asia, Latin America and the Middle East.
Competition is based on the strength of proprietary strains and formulations, scientific evidence of efficacy, regulatory authorisations in key markets, technical support for nutritionists, and access to integrators and premix and feed mill channels. Since 2022, competition has been shaped by consolidation and portfolio restructuring, including the formation of Novonesis, the planned divestment of dsm-firmenich's Animal Nutrition & Health business, and a series of acquisitions of phytogenic and probiotic specialists. Leading companies are increasingly positioning themselves as providers of integrated gut health solutions that combine several eubiotic classes with diagnostics and digital services.
Key Player Positioning
Based on product portfolio breadth, geographic reach, scale and innovation activity, the companies profiled in this study can be grouped into leaders, challengers and niche players. This positioning is qualitative and does not represent numeric market shares.
Leaders dsm-firmenich (Animal Nutrition & Health): Operates one of the broadest gut health portfolios in the industry, built on the former Biomin business, including probiotics (PoultryStar), phytogenics (Digestarom), organic acids (Biotronic, VevoVitall) and precision biotics (Symphiome). The business, which had annualised net sales of about EUR 3.5 billion in 2025, is being divested to CVC Capital Partners, with closing expected at the end of 2026.
Novonesis: Formed in January 2024 through the merger of Novozymes and Chr. Hansen, with net sales of EUR 4,157.6 million in 2025. It offers Bacillus-based probiotics (GalliPro, BioPlus), ruminant probiotics (Bovamine) and silage inoculants, and has full control of its feed enzyme business since June 2025.
Cargill: Through its Animal Nutrition & Health business, Cargill combines Delacon phytogenics, Diamond V postbiotics and Provimi premix capabilities with global reach. Cargill reported revenue of USD 164 billion in fiscal 2026.
ADM: Offers phytogenics (XTRACT, from Pancosma), probiotics (EMPIRA PRO), yeast-based products (CITRISTIM) and organic acid and butyrate products. ADM reported revenue of USD 80.27 billion in 2025, including USD 7.51 billion in its Nutrition segment.
Kemin Industries: A privately held company with annual sales of more than USD 1 billion, Kemin offers probiotics (CLOSTAT, ENTEROSURE), encapsulated butyrate (BUTIPEARL) and water-soluble products, built around its proprietary Bacillus PB6 strain.
Adisseo: Has built a specialty gut health portfolio, including the Alterion probiotic, butyrate and medium-chain fatty acid products, and Nor-Feed plant extracts, alongside its methionine business. Bluestar Adisseo reported revenue of RMB 17.23 billion in 2025.
Challengers
Evonik Industries: Best known for amino acids, Evonik is growing its probiotics business (Ecobiol, GutPlus, GutCare) and more than doubled its probiotic production capacity in León, Spain, in 2023. Group sales were EUR 14.1 billion in 2025.
Lallemand Animal Nutrition: A specialist in yeast and bacterial probiotics (LEVUCELL SB, LEVUCELL SC, BACTOCELL) and yeast derivatives. Its parent, Lallemand Inc., is privately held and does not disclose revenue.
Alltech: A privately held company offering yeast-derived prebiotic products (Actigen), acidifiers and phytogenics (Agolin, Olerix), with a strong global presence. Alltech does not disclose revenue.
Nutreco (Trouw Nutrition): Offers organic acid and phytogenic products under the Selko brand, including the Selko Fytera range launched in 2025. Nutreco reported net revenue of EUR 7.9 billion in 2024.
Novus International: Owned by Mitsui & Co. and Nippon Soda, Novus offers organic acid and essential oil eubiotics (ACTIVATE, AVIMATRIX, NEXT ENHANCE) and has reorganised to grow its specialty feed ingredients business. Novus does not disclose revenue.
Niche Players
Anpario: A UK-based specialist in natural feed additives, including the oregano-based phytogenic Orego-Stim and pHorce acidifiers, with direct-fed microbials added through its 2024 acquisition of Bio-Vet in the United States. Anpario reported revenue of GBP 47.2 million in 2025.
Competitor Dashboard
The dashboard below rates each profiled company as Low, Medium, High or Very High on four parameters: breadth and depth of eubiotic product portfolio, regional presence, strategic alliances, and industry experience.
Threat of New Entrants: Medium
Regulatory authorisation requirements, efficacy data and proprietary strains create significant barriers for biological products such as probiotics.
Barriers are lower for blended organic acid and phytogenic products, where many regional formulators operate.
Established suppliers benefit from long-standing relationships with integrators and premix companies, which new entrants find difficult to replicate.
Bargaining Power of Suppliers: Medium
Organic acid producers depend on petrochemical feedstocks whose prices fluctuate with energy markets.
Several leading eubiotic suppliers are vertically integrated into fermentation or acid production, reducing their dependence on external suppliers.
Inputs for essential oils and plant extracts are subject to agricultural supply variability.
Bargaining Power of Buyers: High
Large integrators and compound feed manufacturers buy in volume and have strong negotiating power.
Buyers increasingly demand trial data and measurable returns before adopting products.
The availability of many competing formulations, especially in organic acids, allows buyers to switch suppliers.
Threat of Substitutes: Medium
Feed enzymes, vaccines, improved biosecurity and management practices can partly substitute for eubiotics in managing gut health.
Antibiotics remain a substitute in markets where their use for growth promotion is still permitted or weakly enforced.
Substitutes tend to complement rather than replace eubiotics in comprehensive gut health programmes.
Intensity of Competitive Rivalry: High
The market includes large multinational suppliers and many regional formulators competing for the same customers.
Product differentiation is often difficult for customers to verify, increasing price competition.
Ongoing mergers, acquisitions and new product launches intensify competition for market position.
Threat of New Entrants: Medium; Regulatory and data barriers for biologicals; lower barriers for blends.
Bargaining Power of Suppliers: Medium; Exposure to petrochemical and agricultural inputs; partial vertical integration.
Bargaining Power of Buyers: High; Concentrated, volume buyers demanding proven returns.
Threat of Substitutes: Medium; Enzymes, vaccines and management practices; residual antibiotic use.
Intensity of Competitive Rivalry: High; Many suppliers, limited differentiation, active consolidation.
Market estimates by geography (2032)
InsightAsia Pacific leads with $104.84M by 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $41.47M | $51.70M | $64.15M | 4.5% | 21% |
| Europe | $53.06M | $65.52M | $80.37M | 4.2% | 26% |
| Asia Pacific | $57.78M | $77.76M | $104.84M | 6.1% | 34% |
| Latin America | $23.80M | $31.26M | $41.09M | 5.6% | 13% |
| Middle East & Africa | $9.17M | $12.01M | $15.74M | 5.5% | 5% |
| Total | $185.29M | $238.25M | $306.19M | 5.2% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$306.19M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Organic Acids | $97.52M | 3.8% | 32% |
| Probiotics | $86.19M | 6.9% | 28% |
| Prebiotics | $64.45M | 5.9% | 21% |
| Essential Oils & Others | $58.02M | 4.4% | 19% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Eubiotics Market covering market dynamics, competitive landscape, and strategic outlook.
The Eubiotics Market market is projected to reach $306.19M by 2032, growing at 5.2% CAGR. The Organic Acids segment holds the largest share.
The eubiotics market is shaped by the interaction of regulatory policy, livestock production economics and scientific advances in animal gut health. The most powerful long-term force has been the global move away from the routine use of antibiotics in feed, which has created demand for alternatives that can protect animal performance without contributing to antimicrobial resistance. At the same time, producers face sustained pressure to improve feed efficiency, while growth in poultry and pork consumption in emerging economies continues to expand the addressable animal population. Restraining factors include inconsistent field performance, the cost of regulatory approval and the price sensitivity of livestock producers. This chapter assesses these factors and their expected impact over the forecast period.
Market Growth Factor Analysis
The table below summarises five macro-level and five micro-level factors influencing the eubiotics market. Each factor is classified by impact type (promoting, inhibiting or steady), and its strength is scored out of 10 for three periods: 2026–2027, 2028–2030 and 2031–2032. A higher score indicates a stronger influence on the market. These scores are analyst assessments based on secondary research and discussions with industry participants, and are intended to indicate relative importance rather than precise measurements.
Regulatory Restrictions on Antibiotic Growth Promoters
The restriction of antibiotics used for growth promotion is the most important structural driver of the eubiotics market. The European Union prohibited the use of antibiotics as growth promoters in feed from 1 January 2006 under Regulation (EC) No 1831/2003, and Regulation (EU) 2019/6 on veterinary medicinal products, applicable since 28 January 2022, further restricts the preventive use of antimicrobials and extends the growth-promoter prohibition to animals and animal products imported into the EU. In the United States, the Food and Drug Administration's Guidance for Industry #213 ended the use of medically important antimicrobials for production purposes in January 2017 and brought their remaining feed uses under veterinary oversight through the Veterinary Feed Directive; Guidance #263, completed in June 2023, moved the remaining over-the-counter medically important antimicrobials to prescription status. China's Ministry of Agriculture and Rural Affairs withdrew growth-promoting antibiotic feed additives from 1 July 2020 under Announcement No. 194, and India banned colistin for use in food-producing animals and animal feed supplements in 2019. Each of these measures removes a tool producers have relied on to manage enteric disease and performance, and organic acids, probiotics, prebiotics and phytogenics are among the main alternatives adopted to fill the gap.
Rising Global Consumption of Poultry Meat and Pork
Population growth, urbanisation and rising incomes in Asia, Latin America, the Middle East and Africa continue to increase demand for animal protein. Poultry meat has been the main source of growth in global meat consumption because it is relatively affordable, efficient to produce and widely accepted across cultures and religions; the OECD-FAO Agricultural Outlook projects poultry to account for the largest share of the increase in global meat consumption over the coming decade. Expansion of poultry and pig production increases the number of animals fed commercial compound feed, which is the main route through which eubiotics are applied. The shift from backyard to integrated, high-density production systems in countries such as India, Vietnam, Indonesia, Brazil and Saudi Arabia is particularly important, because intensive systems place greater stress on animal gut health and make the economic case for feed additives easier to demonstrate. This driver underpins the faster growth forecast for Asia Pacific, Latin America and Middle East & Africa relative to the more mature European and North American markets.
Focus on Feed Efficiency and Production Economics
Feed is the largest single cost in intensive poultry and pig production, so even small improvements in feed conversion ratio translate into meaningful savings for integrators and farmers. Eubiotics support feed efficiency by improving nutrient digestibility, maintaining the integrity of the intestinal lining, and reducing the energy animals spend responding to subclinical gut challenges. Organic acids also lower the pH of feed and the upper digestive tract, which improves protein digestion and reduces pathogen load, while probiotics and prebiotics shape the microbial population towards beneficial species. Producers increasingly assess feed additives on a return-on-investment basis, and suppliers support this with field trials, digital tools and gut health monitoring services. Periods of high grain and soybean meal prices, such as those experienced in 2022, sharpened attention on feed efficiency and reinforced the role of gut health programmes as a lever for cost control rather than an optional expense.
Removal of Pharmacological Zinc Oxide and Advances in Gut Health Science
In the European Union, veterinary medicinal products containing zinc oxide, which were widely used at high doses to prevent post-weaning diarrhoea in piglets, were withdrawn from the market in June 2022 because of environmental concerns and the risk of co-selection for antimicrobial resistance. The change created immediate demand for nutritional strategies to manage the weaning transition, including organic acids, medium-chain fatty acids, probiotics and phytogenic blends, and similar debates are under way in other pig-producing regions. In parallel, advances in microbiome sequencing, strain characterisation and encapsulation have improved suppliers' ability to design products with defined modes of action and to document their effects. Examples include multi-strain Bacillus probiotics, microencapsulated butyrate and essential oils that survive feed processing, and precision biotics designed to modulate microbial metabolism. These developments strengthen the scientific basis for eubiotics and support adoption among technically sophisticated integrators.
Expansion in Emerging Livestock Economies
Many countries in Asia, Latin America, the Middle East and Africa are still in the early stages of restricting antibiotic growth promoters, while their poultry and pig sectors are growing rapidly and becoming more integrated. National action plans on antimicrobial resistance, developed in line with the WHO, FAO and WOAH Global Action Plan, are expected to tighten rules on antimicrobial use over time. Export-oriented producers in Brazil, Thailand and other countries must also meet the requirements of importing markets such as the European Union. Suppliers that combine affordable product formats with local technical support and registrations are well positioned to capture this growth, as reflected in the above-average forecast CAGRs for India, China, Saudi Arabia and Mexico.
Combination, Precision and Data-Driven Gut Health Solutions
Suppliers are increasingly combining different eubiotic classes, such as probiotics with phytogenics, organic acids with essential oils, and prebiotics with postbiotics, to address several mechanisms at once. Combination products and programmes that integrate microbiome analysis, diagnostics and digital performance monitoring allow suppliers to differentiate on demonstrated outcomes rather than price. Examples include Cargill's combination of Diamond V postbiotics with Delacon phytogenics and dsm-firmenich's Symphiome precision biotic launched in 2022. Such solutions offer higher value per tonne of feed and stronger customer relationships.
New Species and Sustainability Applications
Beyond poultry and swine, there is growing interest in eubiotics for aquaculture, ruminants and companion animals. Aquaculture is the fastest-growing source of animal protein globally and faces significant disease and antibiotic-use challenges, while ruminant producers are exploring phytogenics and probiotics to improve rumen efficiency and reduce enteric methane emissions. Companion animal food is a premium segment where probiotics and postbiotics are increasingly used. Sustainability commitments made by food retailers and processors also create opportunities for additives that can demonstrate reduced antibiotic use, lower nitrogen excretion or improved resource efficiency.
Variability of Efficacy Under Field Conditions
The effects of eubiotics depend on many variables, including diet composition, animal age, health status, housing conditions, the level of pathogen challenge and the specific strain or compound used. As a result, responses observed in controlled trials are not always reproduced on commercial farms, and eubiotics rarely deliver the consistent, broad-spectrum protection that in-feed antibiotics provided. Live probiotic products can also lose viability during high-temperature pelleting and storage unless spore-forming strains, encapsulation or post-pelleting application are used. This variability makes some producers cautious about paying for additives whose return is difficult to measure, particularly in markets where antibiotic use is still permitted or weakly enforced.
Cost and Complexity of Regulatory Approval
Feed additives are subject to pre-market authorisation in most major markets. In the European Union, products such as gut flora stabilisers must be evaluated by the European Food Safety Authority and authorised for specific species, strains and inclusion levels, with authorisations granted for ten-year periods and subject to renewal. Dossiers require efficacy studies in each target species as well as safety data for animals, consumers, users and the environment. Comparable but different requirements exist in the United States, China, Brazil and other markets. The cost and time involved favour large companies with established regulatory teams and can delay the commercialisation of new strains, which restrains the pace at which innovations reach the market.
Producer Margin Pressure and Price Sensitivity
Livestock production is a cyclical, low-margin business. When feed costs rise or meat and egg prices fall, producers seek to reduce discretionary spending, and specialty feed additives can be among the first inputs to be reviewed. Price competition is particularly intense for commodity organic acids, where formulators compete on cost, and in emerging markets where smallholder and semi-commercial producers have limited capacity to pay for premium products. This price sensitivity limits the speed of adoption in lower-income markets and constrains margins for suppliers.
Convergence of Biotics and Rise of Postbiotics
The boundaries between probiotics, prebiotics and other categories are becoming less distinct as suppliers develop synbiotics (combinations of probiotics and prebiotics) and postbiotics (inactivated microbial cells or their metabolites). Postbiotics offer stability advantages during feed processing and are gaining attention as a complement to live microbials.
Industry Consolidation and Portfolio Restructuring
The supply base is undergoing significant change. The merger of Novozymes and Chr. Hansen to form Novonesis in January 2024 combined a leading enzyme portfolio with a leading probiotic portfolio, and Novonesis took full control of the former Feed Enzyme Alliance in June 2025. dsm-firmenich agreed in February 2026 to sell its Animal Nutrition & Health business to CVC Capital Partners, while companies such as Cargill, Adisseo and Anpario have acquired phytogenic or probiotic specialists. This consolidation increases the scale and research capacity of leading suppliers but may also create opportunities for focused specialists.
Encapsulation and Targeted Delivery
Microencapsulation, coating and matrix technologies are increasingly used to protect active ingredients during pelleting and to release them at the intended site in the gastrointestinal tract. Coated butyrate, protected organic acids and encapsulated essential oils allow lower inclusion rates and more consistent effects, and are a major area of product development.
Disease Outbreaks and Livestock Supply Shocks
African swine fever has caused major losses in pig herds in Asia and Europe since 2018, and highly pathogenic avian influenza has led to large-scale culling of poultry in North America, Europe, Africa and Asia in recent years. Such outbreaks reduce the number of animals being fed in affected markets and disrupt trade, creating short-term volatility in demand for feed additives, while also reinforcing producer interest in biosecurity and gut health.
The eubiotics value chain extends from the supply of chemical and biological raw materials through manufacturing and formulation to distribution and use on farm. Value is added primarily at the manufacturing stage, where strain selection, fermentation, formulation and encapsulation determine product performance, and at the distribution stage, where technical service and integration into feed formulations influence adoption.
Raw materials and inputs: Organic acids such as formic and propionic acid are produced mainly by chemical synthesis from petrochemical feedstocks, while lactic, citric and fumaric acids are produced by fermentation. Probiotics require microbial strains, fermentation media (sugars, starches and protein sources) and carrier materials. Prebiotics are derived from yeast, chicory, sugar beet and other plant sources, and essential oils are extracted from herbs and spices such as oregano, thyme and cinnamon, or produced as nature-identical compounds.
Manufacturing and formulation: Manufacturers carry out fermentation, extraction, chemical synthesis, blending and encapsulation, and conduct quality control and stability testing. Research and development, including strain discovery and efficacy trials, and regulatory registration are key activities at this stage.
Distribution and channels: Products reach users through direct sales to large integrators and feed manufacturers, through premix companies that incorporate eubiotics into vitamin and mineral premixes, and through distributors and veterinary channels serving smaller compound feed mills and farms. Technical service teams play an important role in demonstrating product value.
End users: The end users are integrated poultry and swine producers, compound feed manufacturers, commercial livestock farms, and producers of ruminant, aquaculture and companion animal feed. Feed nutritionists typically decide which additives are included in formulations.
Eubiotics are regulated primarily as feed additives or feed ingredients rather than as veterinary medicines, provided that no therapeutic claims are made. The main frameworks in key regions are summarised below.
North America
United States: The Federal Food, Drug, and Cosmetic Act governs animal food. Feed ingredients may be approved through a food additive petition or recognised as generally recognised as safe (GRAS); the Association of American Feed Control Officials (AAFCO) maintains ingredient definitions, including the list of microorganisms that may be used in direct-fed microbial products. Following the end of the FDA–AAFCO memorandum of understanding in October 2024, the FDA introduced the Animal Food Ingredient Consultation process. Antibiotic use in feed is governed by Guidance for Industry #209, #213 and #263 and the Veterinary Feed Directive.
Canada: The Canadian Food Inspection Agency (CFIA) regulates livestock feeds under the Feeds Act and Feeds Regulations, and Health Canada removed growth promotion claims for medically important antimicrobials in 2018.
Europe
European Union: Regulation (EC) No 1831/2003 on additives for use in animal nutrition requires pre-market authorisation following a scientific assessment by EFSA. Probiotics and many other eubiotics are authorised as zootechnical additives (for example, as gut flora stabilisers), while organic acids are often authorised as technological additives (preservatives or acidity regulators) or as zootechnical additives. Authorised products are listed in the European Union Register of Feed Additives.
Antimicrobial rules: Regulation (EU) 2019/6 on veterinary medicinal products and Regulation (EU) 2019/4 on medicated feed, both applicable from 28 January 2022, restrict preventive antimicrobial use; the use of veterinary medicinal products containing zinc oxide was ended in June 2022.
United Kingdom: Following its exit from the EU, Great Britain retained Regulation (EC) No 1831/2003 in domestic law, with feed additive authorisations managed by the Food Standards Agency and Food Standards Scotland.
Asia Pacific
China: Feed additives are governed by the Regulations on the Administration of Feed and Feed Additives and must appear in the Feed Additive Catalogue issued by the Ministry of Agriculture and Rural Affairs (MARA). MARA Announcement No. 194 withdrew growth-promoting antibiotic feed additives from 1 July 2020.
India: Compound feed quality is guided by Bureau of Indian Standards specifications such as IS 1374 for poultry feeds, and the Ministry of Health and Family Welfare prohibited the use of colistin in food-producing animals and animal feed supplements in 2019. The National Action Plan on Antimicrobial Resistance (2017) sets the policy framework for antimicrobial stewardship.
Japan: Feed additives are regulated under the Act on Safety Assurance and Quality Improvement of Feed, with inspection carried out by the Food and Agricultural Materials Inspection Center (FAMIC).
Latin America
Brazil: The Ministry of Agriculture and Livestock (MAPA) registers feed additives and has progressively prohibited antimicrobials as performance enhancers, including colistin under Normative Instruction No. 45 of 2016.
Argentina: The National Agri-Food Health and Quality Service (SENASA) regulates the registration of feed and feed additives.
Middle East & Africa
Saudi Arabia: The Saudi Food and Drug Authority (SFDA) regulates feed and feed additives.
South Africa: Farm feeds and feed additives are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act (Act 36 of 1947), administered by the Department of Agriculture.
International standards: The Codex Alimentarius Code of Practice on Good Animal Feeding (CAC/RCP 54-2004) and the WHO Guidelines on Use of Medically Important Antimicrobials in Food-Producing Animals (2017) inform national policies across the region.
The table below lists key product launches, acquisitions, partnerships and expansions by leading eubiotics suppliers from 2022 onward.
Jun 2022: Cargill; Acquisition; Signed a binding agreement to acquire Delacon, an Austrian producer of phytogenic feed additives, following a five-year partnership.
Jul 2022: Kemin Industries; Product Launch; Launched ENTEROSURE, a multi-strain Bacillus probiotic for poultry and livestock targeting C. perfringens, E. coli and Salmonella.
Aug 2022: dsm-firmenich (then DSM); Product Launch; Introduced Symphiome, a precision biotic that modulates gut microbiome metabolism in poultry.
Feb 2023: Adisseo; Acquisition; Completed the acquisition of Nor-Feed, a French producer of plant extract feed additives, agreed in December 2022.
Feb 2023: Evonik Industries; Expansion; More than doubled probiotic production capacity at León, Spain, to 6,000 tonnes per year of final product (Ecobiol, GutCare, Fecinor).
Feb 2023: Evonik Industries; Product Launch; Launched PhytriCare IM, a plant-based feed additive developed with Dr. Eckel Animal Nutrition, in the EU.
May 2023: Alltech; Acquisition; Acquired a majority stake in Agolin, a Swiss producer of essential-oil-based additives for cattle.
May 2023: Lallemand Animal Nutrition; Product Launch; Launched the LALPROBIOME range of yeast and bacteria-based solutions for companion animals.
Jul 2023: Adisseo (Nor-Feed); Expansion; Nor-Feed announced the expansion of its plant extract production facility in Anjou, France.
Oct 2023: Cargill; Product Launch; Introduced Dia-V MB Pro for broilers, combining Diamond V postbiotics with Delacon phytogenics.
Jan 2024: Novonesis; Merger; Completed the merger of Novozymes and Chr. Hansen, combining enzyme and probiotic portfolios.
Mar 2024: Novus International; Acquisition; Completed the acquisition of BioResource International, adding gut health and enzyme capabilities.
Sep 2024: Anpario; Acquisition; Acquired Bio-Vet Inc. (Wisconsin, USA), whose sales are about half direct-fed microbials.
Dec 2024: Kemin Industries; Product Launch; Launched BACTAN, a water-soluble probiotic and phytogenic product for pigs and poultry, in EMENA.
Mar 2025: Novonesis; Partnership; Expanded its distribution partnership with Robinson Bioproducts to cover all of Canada for its probiotics and silage inoculants.
May 2025: Nutreco (Trouw Nutrition); Product Launch; Launched the Selko Fytera range of microencapsulated phytogenics for pigs and poultry.
Jun 2025: Novonesis; Acquisition; Completed the EUR 1.5 billion acquisition of dsm-firmenich's share of the Feed Enzyme Alliance.
Jun 2025: ADM; Expansion; Opened an animal microbiome research centre in Lausanne, Switzerland, focused on biotics for livestock, pets and aquaculture.
Sep 2025: Kemin Industries; Acquisition; Acquired CJ Youtell Biotech, an enzymes and fermentation company with plants in Shandong and Hunan, China.
Nov 2025: Cargill; Expansion; Increased micronutrition production capacity at its facility in Austria by 50% to 30,000 tonnes per year.
Nov 2025: Evonik Industries; Product Launch; Presented an enhanced version of its Ecobiol probiotic at Poultry India 2025.
Feb 2026: dsm-firmenich; Divestment; Agreed to sell its Animal Nutrition & Health business to CVC Capital Partners at an enterprise value of about EUR 2.2 billion.
Feb 2026: ADM and Alltech; Partnership; Launched Akralos, a North American animal feed joint venture combining 44 feed mills, with Alltech as majority owner.
Jun 2026: Alltech; Product Launch; Launched Olerix, a coated phytogenic blend for pigs supporting gut health and feed efficiency.
Jul 2026: Lallemand; Acquisition; Completed the acquisition of BIO-CAT Enzymes & Microbials (USA), adding probiotic and microbial production capacity.
Political
Government action plans on antimicrobial resistance, aligned with the WHO/FAO/WOAH Global Action Plan, encourage reduced antibiotic use in livestock.
Food security policies in import-dependent countries such as Saudi Arabia support investment in domestic poultry production.
Trade policies and import requirements, including EU rules on antimicrobial use in exporting countries, influence production practices globally.
Economic
Feed grain and soybean meal price volatility affects producer margins and willingness to spend on additives.
Rising incomes in emerging economies increase per capita meat and egg consumption.
Energy and petrochemical prices influence the cost of synthetic organic acids.
Social
Consumer demand for meat and eggs produced without antibiotics is increasing, particularly in North America and Europe.
Growing public awareness of antimicrobial resistance as a health threat supports policy action.
Animal welfare expectations encourage practices that improve animal health and reduce disease.
Technological
Advances in microbiome sequencing and strain screening support the development of targeted probiotics.
Encapsulation technologies improve the stability and targeted delivery of acids, butyrate and essential oils.
Digital tools and diagnostics allow producers to monitor gut health and measure additive performance.
Environmental
Restrictions on high-dose zinc oxide reflect concern over heavy-metal accumulation in soil and water.
Improved feed efficiency lowers the environmental footprint of livestock production per unit of output.
Interest in reducing enteric methane emissions from ruminants is creating new applications for phytogenics.
Legal
Pre-market authorisation requirements for feed additives differ between jurisdictions, increasing compliance costs.
Rules on permitted claims prevent eubiotics from being marketed with therapeutic claims without veterinary registration.
Intellectual property protection for strains and formulations shapes competitive dynamics.
Profiles of 106 companies operating in the Eubiotics Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Company Headquarters: Missouri, US Founded: 1991 Workforce: ~800+ Company Working: Novus International manufactures animal health and nutrition products for livestock, poultry, and aquaculture. The products offered by the company include various preservative premixtures, feed supplements, feed additives, nutritional feed acids, chelated trace minerals, feed preservatives, feed antioxidants, and other specialty ingredients. Under its eubiotics products category, the company offers ACIDOMIX, a uniquely formulated blend of organic acids which ensures delivery of its acidification to the lower digestive tract. In addition to its preserving effects, the product has antimicrobial effects that help reduce bacterial contamination levels and energy waste resulting in optimal growth rates. The company has research & development laboratories and manufacturing facilities in more than 35 countries, as well as offices with field staff in an additional 60 countries. Novus International operates as a subsidiary of Mitsui & Co. (U.S.A.) Inc. and Nippon Soda Co., Ltd.
3 interactive charts drawn from the Eubiotics Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Eubiotics Market By Livestock
Global Eubiotics Market By Product Type
Global Eubiotics Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
